Dzire Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 11 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.90 M
- Revenue Growth 31.50%
- Profit Growth 38.37%
- Ebitda 58.44%
- Net Worth 39.67%
- Total Assets 20.78%
About Dzire Pharmaceuticals
Dzire Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 October 2013 and has a history of 11 years and four months. Its registered office is in Hisar, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹0.90 M.
Bhim Mehta and Pardeep Mehta serve as directors at the Company.
Company Details
- Location
Hisar, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233HR2013PTC050628
- Company No.
050628
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Oct 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Dzire Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhim Mehta  | Director | 15-May-2014 | Current |
| Pardeep Mehta | Director | 17-Sep-2021 | Current |
Financial Performance of Dzire Pharmaceuticals.
Dzire Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 31.5% increase. The company also saw a substantial improvement in profitability, with a 38.37% increase in profit. The company's net worth Soared by an impressive increase of 39.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dzire Pharmaceuticals?
In 2020, Dzire Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.90 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jan 2023 | State Bank Of India | ₹0.90 M | Open |
How Many Employees Work at Dzire Pharmaceuticals?
Unlock and access historical data on people associated with Dzire Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dzire Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dzire Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
